Virpax Pharmaceuticals, Inc.: Nasdaq/NYSE listing notice — Virpax regains compliance with Nasdaq periodic filing rule; bid price deficiency remains

Virpax Pharmaceuticals, Inc.

Received Nasdaq notice confirming compliance with periodic filing requirement under Listing Rule 5250(c)(1) as of Dec 7, 2023.
Still subject to prior bid price deficiency (Rule 5550(a)(2)) from April 2023; compliance deadline is April 8, 2024.
No other changes to listing status or business operations disclosed.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 10, 2023 with respect to the Company’s failure to maintain a minimum closing bid price of $1.00 per share on any business day over a thirty consecutive business day period, as required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) which the Company has until April 8, 2024 to comply with.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-095247

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.